Keros Therapeutics, Inc. (KROS) |
|
28.56 1.79 (6.69%)
|
06-26 21:51 |
|
Open: |
27.13 |
Pre. Close: |
26.77 |
|
High:
|
28.64 |
Low:
|
26.7 |
|
Volume:
|
548,227 |
Market Cap:
|
686(M) |
|
|
|
|
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
28.68 - 28.78 |
28.78 - 28.87 |
|
Low:
|
26.43 - 26.55 |
26.55 - 26.66 |
|
Close:
|
28.36 - 28.57 |
28.57 - 28.73 |
|
Technical analysis |
as of: 2022-06-24 4:41:15 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 38.13  One year: 44.1 |
| Support: |
Support1: 24.37 Support2: 20.28 |
| Resistance: |
Resistance1: 32.65 Resistance2: 37.76 |
| Pivot: |
28.86 |
| Moving Average: |
MA(5): 27.39 MA(20): 30.16
MA(100): 47.55 MA(250): 45.37 |
| MACD: |
MACD(12,26): -3.7 Signal(9): -4.2 |
| Stochastic oscillator: |
%K(14,3): 19.6 %D(3): 12.3 |
| RSI: |
RSI(14): 36 |
| 52-week: |
High: 68.29 Low: 24.37 |
| Average Vol(K): |
3-Month: 216 (K) 10-Days: 364 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KROS ] has closed above bottom band by 46.1%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 24 Jun 2022
Redd Kross’ ‘Neurotica,’ a Lost ’80s Power-Pop Classic, Finally Gets Its Due: Album Review - Variety
Fri, 24 Jun 2022
Killer Kross Explains How Infamous Adam Cole Promo Came About - Wrestling Inc.
Thu, 23 Jun 2022
Opponents for NZO and Killer Kross announced for MLW Battle Riot - Cageside Seats
Wed, 22 Jun 2022
Where Will Keros Therapeutics Inc (KROS) Stock Go Next After It Has Gained 0.55% in a Week? - InvestorsObserver
Wed, 22 Jun 2022
Killer Kross vs Matt Cross signed for NYC this Thursday - MLW
Mon, 20 Jun 2022
Remembering Ruffhouse Records, the '90s Philly music label behind hits like Cypress Hill, The Fugees, and 'Jump' - Billy Penn
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
23 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
11.3 (%) |
|
% Held by Institutions
|
87.3 (%) |
|
Shares Short
|
880 (K) |
|
Shares Short P.Month
|
959 (K) |
Stock Financials |
|
EPS
|
-2.69 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.34 |
|
Profit Margin (%)
|
-292.3 |
|
Operating Margin (%)
|
-280.5 |
|
Return on Assets (ttm)
|
-13.5 |
|
Return on Equity (ttm)
|
-23.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-1.5 |
|
Sales Per Share
|
0.85 |
|
EBITDA (p.s.)
|
-2.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-62 (M) |
|
Levered Free Cash Flow
|
-39 (M) |
Stock Valuations |
|
PE Ratio
|
-10.66 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.05 |
|
Price to Sales
|
33.24 |
|
Price to Cash Flow
|
-10.76 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
